The lack of standardization surrounding gene therapy production means process design can be more important than speed to clinic, says Oxford BioMedica’s CCO. The complexities of manufacturing monoclonal antibodies (mAbs) has been ironed out somewhat over the 30+ years of their presence commercially. But for the burgeoning gene therapy sector, there are no standardized mammalian-based platforms, for example, nor tried-and-tested upstream and downstream processes. “Viruses and viral vectors come in many shapes and sizes, each with their own characteristics,” Dave…